Clinical Trial Update: Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases [EARLY_Phase 1]

View source ↗

Summary

An early-phase, first-in-humans trial is testing anti-oxLDL IgM antibodies as a potential treatment for lipid metabolism disorders arising from inborn errors. T…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inborn Errors of Metabolism
• Lipid Metabolism Disorders

Drugs mentioned

• Anti-oxLDL IgM antibodies (anti-oxidized LDL IgM antibodies)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Lipid Metabolism, Inborn Errors | EARLY_Phase 1 | Status: UNKNOWN